Tris Pharma Appoints Michael Magee as Vice President, Quality & Compliance
Tris Pharma Appoints Franchesca Fowler to Chief Compliance Officer and Vice President, General Counsel
Tris Pharma Partners with Perigon Pharmacy 360 to Enhance Access to DYANAVEL® XR Tablets for the Treatment of Attention Deficit Hyperactivity Disorder
Tris Pharma Secures First ex-US Authorizations for Quillivant ER Oral Suspension and Quillivant ER Chewable Tablet for the Treatment of Attention Deficit Hyperactivity Disorder
Tris Pharma Presents Data Reinforcing Limited Abuse Potential of Investigational Pain Therapy Cebranopadol at the 2023 PAINWeek Conference
MONMOUTH JUNCTION, N.J.--(BUSINESS WIRE)--Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on ADHD, pain and neurological disorders, today announced the appointments of Thomas Englese as chief commercial officer and Marc Lesnick, Ph.D., as chief development officer.
The ongoing opioid crisis in the US continues to hit devastating record numbers of deaths. Last year, over 110,000 people died because of opioid overdose, mostly due to the use of fentanyl, a powerful opioid painkiller. While some pharma companies are in the midst of lawsuits and settlements, others are trying to find a way to combat the ongoing epidemic.
MONMOUTH JUNCTION, N.J., Dec. 13, 2022 /PRNewswire/ -- Tris Pharma, Inc. (Tris), a fully integrated, innovation-driven pharmaceutical company focused on CNS disorders, today announced new clinical data from its oral human abuse potential study in patients who are nondependent recreational opioid users, which demonstrate that cebranopadol (TRN-228) possesses significantly less likeability at high doses, above the therapeutic range versus immediate release (IR) formulations of tramadol or oxycodone. These data suggest that cebranopadol has a lower potential for abuse versus both C-II and C-IV opioids.